Core Viewpoint - The company has entered into an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million, which aligns with its strategy to expand its innovative drug delivery technology portfolio and global outreach [1][2]. Group 1: Acquisition Details - The buyer, Nova Pneuma Incorporated, a wholly-owned subsidiary of the company, will acquire all assets related to Alexza's business, including properties, equipment, materials, patents, and other intellectual property [1]. - The total purchase price for the assets is set at $15 million [1]. Group 2: Strategic Alignment - The acquisition supports the company's strategy to expand its product portfolio through the Staccato® platform, which has a wide range of therapeutic potential [2]. - The assets acquired are expected to complement the existing product pipeline and create synergies [2]. - The agreement with UCB, a leading biopharmaceutical company in the epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2].

Group 1 - The company, Lee's Pharmaceutical Holdings Limited, announced an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million [1] - The acquired assets include all properties, equipment, materials (including work-in-progress), patents, intellectual property, technical know-how, rights, and assigned contracts associated with Alexza's business [1] Group 2 - The acquisition aligns with the company's strategy to expand its innovative drug delivery technology portfolio through the Staccato platform, which covers a wide range of indications [2] - The assets will complement the company's existing product pipeline and create synergies, enhancing value for the company and its shareholders [2] - The agreement with UCB, a leading biopharmaceutical company in the global epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2]

Group 1 - The company Li's Pharmaceutical (00950) announced an asset purchase agreement with Nova Pneuma Incorporated to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million [1] - The acquired assets include all properties, equipment, materials (including work-in-progress), patents, intellectual property, technical know-how, rights, and assigned contracts associated with Alexza's business [1] Group 2 - The acquisition aligns with the company's strategy to expand its innovative drug delivery technology portfolio through the Staccato platform, which covers a wide range of indications [2] - The acquired assets are expected to create value for the company and its shareholders, with a focus on Staccato One Breath Technology, which has broad therapeutic potential [2] - The agreement with UCB, a leading biopharmaceutical company in the global epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2]